SEARCH

SEARCH BY CITATION

References

  • AUBOEUF, D., RIEUSSET, J., FAJAS, L., VALLIER, P., FRERING, V., RIOU, J.P., STAELS, B., AUWERX, J., LAVILLE, M. & VIDAL, H. (1997). Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes, 46, 13191327.
  • BAKER, C.S., HALL, R.J., EVANS, T.J., POMERANCE, A., MACLOUF, J., CREMINON, C., YACOUB, M.H. & POLAK, J.M. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arteriscler. Thromb. Vasc. Biol., 19, 646655.
  • BENZ, D.J., MOL, M., EZAKI, M., MORI-ITO, N., ZELAN, I., MIYANOHARA, A., FRIEDMAN, T., PARTHASARATHY, S., STEINBERG, D. & WITZTUM, J.L. (1995). Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. J. Biol. Chem., 270, 51915197.
  • BERLINER, J.A. & HEINECKE, J.W. (1996). The role of oxidized lipoproteins in atherogenesis. Free Radical Biol. Med., 20, 707727.
  • BISHOP-BAILEY, D. & HLA, T. (1999). Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14 prostaglandin J2. J. Biol. Chem., 274, 1704217048.
  • BISHOP-BAILEY, D., HLA, T. & MITCHELL, J.A. (1999). Cyclo-oxygenase-2 in vascular smooth muscle. Int. J. Mol. Med., 3, 4148.
  • BISHOP-BAILEY, D., LARKIN, S.W., PEPPER, J.R. & MITCHELL, J.A. (1998). Differential induction of cyclo-oxygenase-2 human venous and arterial vascular smooth muscle cells: role of endogenous prostanoids. Arterioscler. Thromb. Vasc. Biol., 18, 16551661.
  • BISHOP-BAILEY, D., PEPPER, J.R., HADDAD, E-L., NEWTON, R., LARKIN, S.W. & MITCHELL, J.A. (1997). Induction of cyclo-oxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler. Thromb. Vasc. Biol., 17, 16441648.
  • BJORKLUND, S., ALMOUZNI, G., DAVIDSON, I., NIGHTINGALE, K.P. & WEISS, K. (1999). Global transcription regulators of eukaryotes. Cell, 96, 759767.
  • BOEHM, M., ZHANG, L., ZHI, L., MCCLURG, M., BERGER, E., WAGONER, M., MAIS, D., SUTO, C., DAVIES, J., HEYMAN, R. & NADZAN, A.M. (1995). Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem., 38, 31463155.
  • BRAISSANT, O., FOUFELLE, F., SCOTTO, C., DAUCA, M. & WAHLI, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue ditribution of PPARα, -β, and -γ in the adult rat. Endocrinology, 137, 354366.
  • BRANDT, J.M., DJOUADI, F. & KELLY, D.P. (1998). Fatty acids activate transcription of the muscle arnitine palmitoyltransferase I gene in cardiac myocytes via peroxisome proliferator-activated receptor α. J. Biol. Chem., 273, 2378623792.
  • BREITBART, E., SOFER, Y., SHAINBERG, A. & GROSSBERG, S. (1996). Lipoxygenase activity in heart cells. FEBS Lett., 395, 148152.
  • BROCKMAN, J.A., GUPAT, R.A. & DUBOIS, R.N. (1998). Activation of PPARγ leads to inhibtion of anchorage-independent growth of human colorectal cancer cells. Gastroenterology, 115, 10491055.
  • BRUN, R.P., TONTONOZ, P., FORMAN, B.M., ELLIS, R., CHEN, J., EVANS, R.M. & SPIEGELMAN, B.M. (1996). Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev., 10, 974984.
  • CHAMBON, P. (1996). A decade of molecular biology of retinoic acid receptors. FASEB J., 10, 940954.
  • CHINETTI, G., GRIGLIO, S., ANTONUCCI, M., TORRA, I.P., DELERIVE, P., MAJD, Z., FRUCHART, J-C., CHAPMAN, J., NAJIB, J. & STAELS, B. (1998). Activation of peroxisome proliferator-activated receptor α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem., 273, 2557325580.
  • CLARK, R.B., BISHOP-BAILEY, D., ESTRADA-HERNANDEZ, T., HLA, T., PUDDINGTON, L. & PADULA, S.J. (1999). The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J. Immunol. In press.
  • CYRUS, T., WITZTUM, J.L., RADER, D.J., TANGIRALA, R., FAZIO, S., LINTON, M.F. & FUNK, C. (1999). Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo-E deficient mice. J. Clin. Invest., 103, 15971604.
  • DELERIVE, P., MARTIN-NIZARD, F., CHINETTI, G., TROTTEIN, F., FRUCHART, J.C., NAJIB, J., DURIEZ, P. & STAELS, B. (1999). Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signalling pathway. Circ. Res., 85, 394402.
  • DEMETRI, G.D., FLETCHER, C.D.M., MUELLER, E., SARRAF, P., NAUJOKS, R., CAMPBELL, N., SPIEGELMAN, B.M. & SINGER S. (1999). Induction of solid tumour differentiation by the peroxisome proliferator-activated receptor γ ligand troglitizone in patients with liposarcoma. Proc. Natl. Acad. Sci. U.S.A., 96, 39513956.
  • DEVCHAND, P.R., KELLER, H., PETERS, J.M., VAZQUEZ, M., GONZALEZ, F.J. & WAHLI, W. (1996). The PPARα- leukotriene B4 pathway to inflammation control. Nature, 384, 3943.
  • DJOUADI, F., WEINHEIMER C.J., SAFFITZ, J.E., PITCHFORD, C., BASTIN, J., GONZALEZ, F.J. & KELLY, D.P. (1998). A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice. J. Clin. Invest., 102, 10831091.
  • DREXLER, H. & HORNIG, B. (1999). Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol., 31, 5160.
  • DREYER, C., KREY, G., KELLER H., GIVEL, F., HELFTENBEIN, G. & WAHLI, W. (1992). Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 68, 879887.
  • EGUCHI, Y., EGUICHI, N., ODA, H., SEIKI, K., KIJIMA, Y., MATSU-URA, Y., URADE, Y. & HAYAISHI, O. (1997). Expression of lipocalin-type prostaglandin D synthase (β-trace) in human hearts and its accumulation in the coronary circulation of angina patients. Proc. Natl. Acad. Sci. U.S.A., 94, 1468914694.
  • FEINMARK, S.J. & CORNICELLI, J.A. (1997). Is there a role for 15-lipoxygenase in atherogenesis. Biochem. Pharmacol., 54, 953959.
  • FOLKMAN, J. (1995). Angiogenesis in cancer, vascular rheumatoid and other disease. Nature Med., 1, 2731.
  • FORMAN, B.M., CHEN, J. & EVANS, R.M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U.S.A., 94, 43124317.
  • FORMAN, B.M., TONTONOZ, P., CHEN, J., BRUN, R.P., SPIEGELMAN, B.M. & EVANS, R.M. (1995). 15-Deoxy-Δ-12,14- prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell, 83, 803812.
  • FUNK, C.D. (1996). The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase deficient mice. Biochim. Biophys. Acta., 1304, 6584.
  • GLASS, C.K. (1994). Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocrinol. Rev., 15, 391407.
  • GOTTLICHER, M., WIDMARK, E., LI, Q. & GUSTAFSSON, J.A. (1992). Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A., 89, 46534657.
  • GREENE, M.E., BLUMBERG, B., MCBRIDE, O.W., YI, H.F., KRONQUIST K., KWAN, K., HSIEH, L., GREENE, G. & NIMER, S.D. (1995). Isolation of the human peroxisome proliferator-activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Exp., 4, 281299.
  • HLA, T. & NIELSON, K. (1992). Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A., 89, 73847388.
  • HUANG, J.T., WELCH, J.S., RICOTE, M., BINDER, C.J., WILLSON, T.M., KELLY, C., WITZTUM, J.L., FUNK, C.D., CONRAD, D. & GLASS, C.K. (1999). Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature, 400, 378382.
  • INOUE, I., SHINO, K., NOJI, S., AWATA, T. & KATAYAMA, S. (1998). Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun., 246, 370374.
  • ISSEMANN, I. & GREEN, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645650.
  • JIANG, C., TING, A.T. & SEED, B. (1998). PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 8286.
  • JOW, L. & MUKHERJEE, R. (1995). The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPARα and thyroid hormone receptors. J. Biol. Chem., 270, 38363840.
  • KIM, J.B., WRIGHT, H.M., WRIGHT, M. & SPIEGELMAN, B. (1998). ADD1/SREBP1 activates PPARγ through the production of endogenous ligand. Proc. Natl. Acad. Sci. U.S.A., 95, 43334337.
  • KLIEWER, S.A., FORMAN, B.M., BLUMBERG, B., ONG, E.S., BORGMEYER, U., MANGELSDORF, D.J., UMESONO, K. & EVANS, R.M. (1994). Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A., 91, 73557359.
  • KLIEWER, S.A., LENHARD, J.M., WILLSON, T.M., PATEL, I., MORRIS, D.C. & LEHMANN, J.M. (1995). A prostaglandin J metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell, 83, 813819.
  • KLIEWER, S.A., SUNDSETH, S.S., JONES, S.A., BROWN, P.J., WISELY, G.B., KOBLE, C.S., DEVCHAND, P., WAHLI, W., WILLSON, T.M., LENHARD, J.M. & LEHMAN, J.M. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. U.S.A., 94, 43184323.
  • KLIEWER, S.A., UMESONO, K., NOONAN, D.J., HEYMAN, R.A. & EVANS, R.M. (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature, 358, 771774.
  • KUBOTA, T., KOSHIZUKA, K., WILLIAMSON, E.A., ASOU, H., SAID, J.W., HOLDEN, S., MIYOSHI, I. & KOEFFLER, H.P. (1998). Ligand for peroxisome proliferator-activated receptor γ (troglitizone) has potent antitumour effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58, 33443352.
  • LAW, R.E., MEEHAN, W., XI, X-P., GRAF, K., WUTHRICH, D.A., COATS, W., FAXON, D. & HSUEH, W.A. (1996). Troglitizone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest., 98, 18971905.
  • LEHMANN, J.M., LENHARD, J.M., OLIVER, B.B., RINGOLD, G.M. & KLIEWER, S.A. (1997). Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steriodal antiinflammatory drugs. J. Biol. Chem., 272, 34063410.
  • LOSKUTOFF, D.J. & SAMAD, F. (1997). The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arteriscler. Thromb, Vasc. Biol., 18, 16.
  • MA, H., SPRECHER, H.W. & KOLATTUKUDY, P.E. (1998). Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ-expressing tissue. J. Biol. Chem., 273, 3013130138.
  • MALLAT, Z., NAKAMURA, T., OHAN, J., LESECHE, G., TEDGUI, A., MACLOUF, J. & MURPHY, R.C. (1999). The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest., 103, 421427.
  • MANGELSDORF, D.J., BORGMEYER, U., HEYMAN, R.A., ZHOU, J.Y., ONG, E.S., ORO, A.E., KAKIZUKA, A. & EVANS, R.M. (1992). Characterisation of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev., 6, 329344.
  • MANGELSDORF, D.J. & EVANS, R.M. (1995). The RXR heterodimers and orphan receptors. Cell, 83, 841850.
  • MANGELSDORF, D.J., ONG, E.S., DYCK, J.A. & EVANS, R.M. (1990). Nuclear receptor that identifies a novel retinoic acid response pathway. Nature, 345, 224229.
  • MARX, N., BOURCIER T., SUKHOVA, G.K., LIBBY, P. & PLUTZKY, J. (1999a). PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression. Arterioscler. Thromb. Vasc. Biol., 19, 546551.
  • MARX, N., SCHONBECK, U., LAZAR, M.A., LIBBY, P. & PLUTZKY, J. (1998a). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res., 83, 10971103.
  • MARX, N., SUKHOVA, G.K., COLLINS, T., LIBBY, P. & PLUTZKY, J. (1999b). PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 99, 31253131.
  • MARX, N., SUKHOVA, G., MURPHY, C., LIBBY, P. & PLUTZKY, J. (1998b). Macrophages in human atheroma contain PPARγ. Am. J. Pathol., 153, 1723.
  • MITCHELL, J.A., AKARASEREENONT, P., THIEMERMANN, C., FLOWER, R.J. & VANE, J.R. (1993). Selectivity of nonsteriodal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A., 90, 1169311697.
  • MUELLER, E., SARRAF, P., TONTONOZ, P., EVANS, R.M., MARTIN, K.J., ZHANG, M., FLETCHER, C., SINGER, S. & SPIEGELMAN, B.M. (1998). Terminal differentiation of human breast cancer through PPARγ. Mol. Cell., 1, 465470.
  • MUKHERJEE, R., JOW, L., CROSTON, G.E. & PATERNITI, J.R. (1997). Identification, characterisation, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem., 272, 80718076.
  • NAGY, L., TONTONOZ, P., ALVAREZ, J.G.A., CHEN, H. & EVANS, R.M. (1998). Oxidised LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell, 93, 229240.
  • NARKO, K., RISTIMAKI, A., MACPHEE, M., SMITH, E., HAUDENSCHILD, C.C. & HLA, T. (1997). Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J. Biol. Chem., 272, 2145521460.
  • NEWBY, A.C. & ZALTSMAN, A.B. (1999). Fibrous cap formation or destruction–the critical importance of vascular smooth muscle cell proliferation, migration, and matrix formation. Cardiovasc. Res., 41, 345360.
  • NOLTE, R.T., WISELY, G.B., WESTIN, S., COBB, J.E., LAMBERT, M.H., KUROKAWA, R., ROSENFELD, M.G., WILLSON, T.M., GLASS, C.K. & MILBURN, M. (1998). Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature, 395, 137143.
  • O'BANION, M.K., WINN, V.D. & YOUNG, D.A. (1992). cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A., 89, 48884892.
  • OBERFIELD, J.L., COLLINS, J.L., HOLMES, C.P., GOREHAM, D.M., COOPER, J.P., COBB, J.E., LENHARD, J.M., HULL-RYDE, E.A., MOHR, C.P., BLANCHARD, S.G., PARKS, D.J., MOORE, L.B., LEHMANN, J.M., PLUNKET, K., MILLER, A.B., MILBURN, M.V., KLIEWER, S.A. & WILLSON, T.M. (1999). A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U.S.A., 96, 61026106.
  • REGINATO, M.J., BAILEY, S.T., KRAKOW, S.L., MINAMI, C., ISHII, S., TANAKA, H. & LAZAR, M.A. (1998a). A potent antidiabetic thiazoldinedione with unique peroxisome proliferator-activated receptor γ- activating properties. J. Biol. Chem., 273, 3267932684.
  • REGINATO, M.J., KRAKOW, S.L., BAILEY, S.T. & LAZAR, M.A. (1998b). Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ. J. Biol. Chem., 273, 18551858.
  • RICOTE, M., HUANG, J., FAJAS, L., LI, A., WELCH, J., NAJIB, J., WITZTUM, J.L., AUWERX, J., PALINSKI, W. & GLASS, C.K. (1998b). Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidised low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A., 95, 76147619.
  • RICOTE, M., LI, A.C., WILLSON, T.M., KELLY, C.J. & GLASS, C.K. (1998a). The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature, 391, 7982.
  • RISTOW, M., MULLER-WIELAND, D., PFEIFFER, A., KRONE, W. & KAHN C.R. (1998). Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New. Eng. J. Med., 339, 953959.
  • ROSS, R. (1999). Atherosclerosis–an inflammatory disease. New Eng. J. Med., 340, 115126.
  • RUSCHITZKA, F.T., NOLL, G. & LUSCHER, T.F. (1997). The endothelium in coronary artery disease. Cardiology, 88, 319.
  • SARRAF, P., MUELLER, E., JONES, D., KING, F.J., DEANGELO, D.J., PARTRIDGE, J.B., HOLDEN, S.A., CHEN, L.B., SINGER, S., FLETCHER, C. & SPIEGELMAN, B.M. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARγ Nature Med., 4, 10461052.
  • SATOH, H., TSUKAMOTO, K., HASHIMOTO, Y., HASHIMOTO, N., TOGO, M., HARA, M., MAEKAWA, H., ISOO, N., KIMURA, S., WATANABE, T. (1999). Thiazoldinediones suppress endothelin-1 secretion from bovine endothelial cells: a new possible role for PPARγ on vascular endothelial function. Biochem. Biophys. Res. Commun., 254, 757763.
  • SCHMIDT, A., ENDO, N., RUTLEDGE, S.J., VOGEL, R., SHINAR, D. & RODAN, G.A. (1992). Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol., 6, 16341641.
  • SHER, T., YI, H-F., MCBRIDE, O.W. & GONZALEZ, F.J. (1993). cDNA cloning, chromosomal mapping, and functional characterisation of the human peroxisome proliferator-activated receptor. Biochemistry, 32, 55985604.
  • SIGAL, E., LAUGHTON, C.W. & MULKINS, M.A. (1994). Oxidation, lipoxygenase, and atherogenesis. Ann. N.Y. Acad. Sci., 714, 211224.
  • SMITH, W.L., DEWITT, D.L. & ALLEN, M.L. (1983). Bimodal distribution of the PGI2 synthase antigen in smooth muscle cells. J. Biol. Chem., 258, 49224926.
  • SMITH, W.L., MARNETT, L.J. & DEWITT, D.L. (1991). Prostaglandin and thromboxane biosynthesis. Phamac. Ther., 49, 153179.
  • SONG, J., WALSH, M.F., IGWE, R., RAM, J.L., BARAZI, M., DOMINGUEZ, L.J. & SOWERS, J.R. (1997). Troglitizone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes, 46, 659664.
  • SPIEGELMAN, B.M. (1998). PPARγ: Adipogenic regulator and thiazoldinedione receptor. Diabetes, 47, 507514.
  • SPIEGELMAN, B.M. & FLIER, J.S. (1996). Adipogenesis and obesity: rounding out the big picture. Cell, 87, 377389.
  • STAELS, B., DALLONGEVILLE, J., AUWERX, J., SCHOONJANS, K., LEITERSDORF, E. & FRUCHART, J-C. (1998b). Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98, 20882093.
  • STAELS, B., KOENIG, W., HABIB, A., MERVAL, R., LEBRET, M., TORRA, I.P., DELERIVE, P., FABEL, A., CHINETTI, G., FRUCHART, J-C., NAJIB, J., MACLOUF, J. & TEDGUI, A. (1998a). Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature, 393, 790793.
  • STEINBERG, D. (1997). Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem., 272, 2096320966.
  • TONTONOZ, P., NAGY, L., ALVAREZ, J.G.A., THOMAZY, V.A. & EVANS, R.M. (1998). PPARγ promotes monocyte/macrophage differentiation and uptake of oxidised LDL. Cell, 93, 241252.
  • TORCHIA, J., GLASS, C. & ROSENFELD, M.G. (1998). Co-activators and co-repressors in the integration of transcriptional responses. Curr. Opin. Cell Biol., 10, 373383.
  • TSUJII, M., KAWANO, S., TSUJI, S., SAWAOKA, H., HORI, M. & DUBOIS, R.N. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705716.
  • TUGWOOD, J.D., ISSEMANN, I., ANDERSON, R.G., BUNDELL, K.R., MCPHEAT, W.L. & GREEN S. (1992). The mouse peroxisome proliferator-activated receptor recognises a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J., 11, 433439.
  • UPPENBERG, J., SVENSSON, C., JAKI, M., BERTILSSON, G., JENDEBERG, L. & BERKENSTAM, A. (1998). Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J. Biol. Chem., 273, 3110831112.
  • XIN, X., YANG, S., KOWALSKI, J. & GERRITSEN, M.E. (1999). Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem., 274, 91169121.
  • XU, H.E., LAMBERT, M.H., MONTANA, V.G., PARKS, D.J., BLANCHARD, S.G., BROWN, P.J., STERNBACH, D.D., LEHMANN, J., WISELY, G.B., WILLSON, T.M., KLIEWER, S.A. & MILBURN. (1999). Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell, 3, 397403.
  • YLA-HERTTUALA, S., ROSENFELD, M.E., PARTHASARATHY, S., GLASS, C.K., SIGAL, E., WITZTUM, J.L. & STEINBERG, D. (1990). Co-localisation of 15-lipoxygenase mRNA and protein with epitopes of oxidised LDL in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. U.S.A., 87, 69596963.
  • YLA-HERTTUALA, S., ROSENFELD, M.E., PARTHASARATHY, S., SIGAL, E., SARKIOJA, T., WITZTUM, J.L. & STEINBERG, D. (1991). Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific- lipid protein aducts. J. Clin. Invest., 87, 11461152.
  • YU, G.S., LU, Y.C. & GULICK, T. (1998). Co-regulation of tissue specific alternative human carnitine palmitoyltransferase Iβ gene promoters by fatty acid enzyme substrate. J. Biol. Chem., 273, 3290132909.
  • YU, K., BAYONA, W., KALLEN, C.B., HARDING, H.P., RAVERA, C.P., MCMAHON, G., BROWN, M. & LAZAR, M. (1995). Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem., 270, 2397523983.
  • ZHANG, F., SOWERS, R.J., RAM, J.L., STANDLEY, P.R. & PEULER, J.D. (1994). Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension, 24, 170175.
  • ZHU, Y., ALVARES, K., HUANG, Q., RAO, M.S. & REDDY, J.K. (1993). Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem., 268, 2681726820.
  • ZHU, Y., QI, C., CALANDRA, C., RAO, M.S. & REDDY, J.K. (1996). Cloning and identification of mouse steriod receptor co-activator-1 (mSRC-1), as a co-activator or peroxisome proliferator-activated receptor-γ. Gene Exp., 6, 185195.
  • ZHU, Y., Qi, C., JAIN, S., RAO, M.S. & REDDY, J.K. (1997). Isolation and characterisation of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J. Biol. Chem., 272, 2550025506.